Abstract
Promoting osteogenic differentiation and efficacious bone regeneration have the potential to revolutionize the treatment of orthopaedic and musculoskeletal disorders. Mesenchymal Stem Cells (MSCs) are bone marrow progenitor cells that have the capacity to differentiate along osteogenic, chondrogenic, myogenic, and adipogenic lineages. Differentiation along these lineages is a tightly controlled process that is in part regulated by the Bone Morphogenetic Proteins (BMPs). BMPs 2 and 7 have been approved for clinical use because their osteoinductive properties act as an adjunctive treatment to surgeries where bone healing is compromised. BMP-9 is one of the least studied BMPs, and recent in vitro and in vivo studies have identified BMP-9 as a potent inducer of osteogenic differentiation in MSCs. BMP-9 exhibits significant molecular cross-talk with the Wnt/ β-catenin and other signaling pathways, and adenoviral expression of BMP-9 in MSCs increases the expression of osteogenic markers and induces trabecular bone and osteiod matrix formation. Furthermore, BMP-9 has been shown to act synergistically in bone formation with other signaling pathways, including Wnt/ β-catenin, IGF, and retinoid signaling pathways. These results suggest that BMP-9 should be explored as an effective bone regeneration agent, especially in combination with adjuvant therapies, for clinical applications such as large segmental bony defects, non-union fractures, and/or spinal fusions.
Keywords: BMP-9, GDF-2, bone formation, mesenchymal stem cells, fracture healing, bone regeneration, cell-based gene therapy, -catenin, osteogenic, spinal fusions, trabecular bone
Current Gene Therapy
Title: BMP-9 Induced Osteogenic Differentiation of Mesenchymal Stem Cells: Molecular Mechanism and Therapeutic Potential
Volume: 11 Issue: 3
Author(s): Ke Yang, Tong-Chuan He, Rex C. Haydon, Hue H. Luu, Russell R. Reid, Zhong-Liang Deng, Guo-Wei Zuo, Bai-Cheng He, Liang Chen, Yuxi Su, Hong Liu, Ning Hu, Mi Li, Xing Liu, Richard Rames, Gaurav Luther, Enyi Huang, Jian-Li Gao, Stephanie H. Kim, Qiong Shi, Chad Teven, Jinyong Luo, Xiaoji Luo, Yang Bi, Joseph Lamplot, Qing Luo, Quan Kang, Gaohui Zhu and Eric R. Wagner
Affiliation:
Keywords: BMP-9, GDF-2, bone formation, mesenchymal stem cells, fracture healing, bone regeneration, cell-based gene therapy, -catenin, osteogenic, spinal fusions, trabecular bone
Abstract: Promoting osteogenic differentiation and efficacious bone regeneration have the potential to revolutionize the treatment of orthopaedic and musculoskeletal disorders. Mesenchymal Stem Cells (MSCs) are bone marrow progenitor cells that have the capacity to differentiate along osteogenic, chondrogenic, myogenic, and adipogenic lineages. Differentiation along these lineages is a tightly controlled process that is in part regulated by the Bone Morphogenetic Proteins (BMPs). BMPs 2 and 7 have been approved for clinical use because their osteoinductive properties act as an adjunctive treatment to surgeries where bone healing is compromised. BMP-9 is one of the least studied BMPs, and recent in vitro and in vivo studies have identified BMP-9 as a potent inducer of osteogenic differentiation in MSCs. BMP-9 exhibits significant molecular cross-talk with the Wnt/ β-catenin and other signaling pathways, and adenoviral expression of BMP-9 in MSCs increases the expression of osteogenic markers and induces trabecular bone and osteiod matrix formation. Furthermore, BMP-9 has been shown to act synergistically in bone formation with other signaling pathways, including Wnt/ β-catenin, IGF, and retinoid signaling pathways. These results suggest that BMP-9 should be explored as an effective bone regeneration agent, especially in combination with adjuvant therapies, for clinical applications such as large segmental bony defects, non-union fractures, and/or spinal fusions.
Export Options
About this article
Cite this article as:
Yang Ke, He Tong-Chuan, C. Haydon Rex, H. Luu Hue, R. Reid Russell, Deng Zhong-Liang, Zuo Guo-Wei, He Bai-Cheng, Chen Liang, Su Yuxi, Liu Hong, Hu Ning, Li Mi, Liu Xing, Rames Richard, Luther Gaurav, Huang Enyi, Gao Jian-Li, H. Kim Stephanie, Shi Qiong, Teven Chad, Luo Jinyong, Luo Xiaoji, Bi Yang, Lamplot Joseph, Luo Qing, Kang Quan, Zhu Gaohui and R. Wagner Eric, BMP-9 Induced Osteogenic Differentiation of Mesenchymal Stem Cells: Molecular Mechanism and Therapeutic Potential, Current Gene Therapy 2011; 11 (3) . https://dx.doi.org/10.2174/156652311795684777
DOI https://dx.doi.org/10.2174/156652311795684777 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets The DREAM of Pain Relief
Current Rheumatology Reviews Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design Natural Polymers Based Hydrogels for Cell Culture Applications
Current Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Using a Hybrid Radioenhancer to Discover Tumor Cell-targeted Treatment for Osteosarcoma: An In Vitro Study
Current Medicinal Chemistry Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
Current Signal Transduction Therapy Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC)
Current Cancer Drug Targets Quadruplex-Forming Oligonucleotides as Tools in Anticancer Therapy and Aptamers Design: Energetic Aspects
Current Medicinal Chemistry - Anti-Cancer Agents Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Reversion of Multidrug Resistance Using Self-Organized Nanoparticles Holding Both Doxorubicin and Targeting Moiety
Letters in Drug Design & Discovery Application of Selenium Nanoparticles in Localized Drug Targeting for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development
Current Molecular Pharmacology